

Notes on the consolidated balance sheet

13. CASH AND CASH EQUIVALENTS

As of December 31, cash and cash equivalents were as follows:

in million €	2008	2007
Cash	361	349
Securities (with a maturity of up to 90 days)	9	12
Total cash and cash equivalents	370	361

As of December 31, 2008 and December 31, 2007, committed funds of €78 million and €65 million, respectively, were included in cash and cash equivalents.

14. TRADE ACCOUNTS RECEIVABLE

As of December 31, trade accounts receivable were as follows:

in million €	2008	2007
Trade accounts receivable	2,734	2,382
less allowance for doubtful accounts	257	223
Trade accounts receivable, net	2,477	2,159

All trade accounts receivable are due within one year.

The following table shows the development of the allowance for doubtful accounts during the fiscal year:

in million €	2008	2007
Allowance for doubtful accounts at the beginning of the year	223	218
Change in valuation allowances as recorded in the consolidated statement of income	159	152
Write-offs and recoveries of amounts previously written-off	-129	-132
Foreign currency translation	4	-15
Allowance for doubtful accounts at the end of the year	257	223

The following table shows the ageing analysis of trade accounts receivable and their allowance for doubtful accounts:

in million €	not overdue	up to 3 months overdue	3 to 6 months overdue	6 to 12 months overdue	more than 12 months overdue	Total
Trade accounts receivable	1,566	459	233	188	288	2,734
less allowance for doubtful accounts	8	28	31	42	148	257
Trade accounts receivable, net	1,558	431	202	146	140	2,477

15. INVENTORIES

As of December 31, inventories consisted of the following:

in million €	2008	2007
Raw materials and purchased components	289	209
Work in process	180	129
Finished goods	713	579
less reserves	55	42
Inventories, net	1,127	875

The companies of the Fresenius Group are obliged to purchase approximately €1,940 million of raw materials and purchased components under fixed terms, of which €344 million was committed at December 31, 2008 for 2009. The terms of these agreements run one to ten years. Advance payments from customers of €83 million (2007: €6 million) have been offset against inventories.

Inventories as of December 31, 2008 and December 31, 2007 included approximately €25 million and approximately €21 million, respectively, of the product Erythropoietin (EPO),